I-131 tositumomab [96] |
Anti-CD20 radioimmunotherapy |
Previously untreated DLBCL (with R-CHOP) |
|
No |
1-year PFS rate: 75%; 1-year OS rate: 83% |
Inotuzumab ozogamicin (CMC-544) [93] |
CD22 targeted cytotoxic immunoconjugate |
R/R CD22+ and CD20+ NHL (with R) |
I |
No |
ORR: 80%; 1-year PFS rate: 89% |
Inotuzumab ozogamicin (CMC-544) [94] |
CD22 targeted cytotoxic immunoconjugate |
R/R CD22+ and CD20+ DLBCL prior to HDT-ASCT (with R) |
|
No |
ORR: 21% |
90Y-epratuzumab tetraxetan [92] |
Radiolabeled humanized anti-CD22 mAb |
R/R NHL |
I/II |
Dose-finding |
ORR: 62%; CR/CRu: 48%; mPFS: 9.5 months |
90Y-epratuzumab tetraxetan [97] |
Radiolabeled humanized anti-CD22 mAb |
Consolidation after first-line R-CHOP in DLBCL |
II |
No |
Improved remission status 6 weeks after RIT: 30.7% |
Brentuximab vedotin (SGN-35) [104] |
Antitubulin monomethyl auristatin E (MMAE) anti-CD30 mAb conjugate |
R/R lymphoma |
I |
|
ORR: 46%; CR: 29% |